Ra-223 in a Patient with Marrow Replacement
A 72-year-old man with metastatic castration-resistant prostate cancer and bone metastases has progressed after docetaxel and enzalutamide. He is referred for Ra-223. Laboratory values are: hemoglobin 9.7 g/dL, platelets 86,000/µL, ANC 1.3 × 10^9/L, creatinine 1.4 mg/dL, ALP 320 U/L, and PSA 62 ng/mL. He has received two red-cell transfusions in the past 6 months. MRI shows diffuse marrow replacement in the lumbar spine and pelvis. He takes denosumab and has no prior fracture. His bone pain requires oxycodone. He asks whether Ra-223 will prolong his life and whether he can start next week.
1. Is he eligible for Ra-223 now? Justify your answer using the label criteria and the clinical picture.
Read the worked answer
He is not eligible now. The Ra-223 label requires an absolute neutrophil count of at least 1.5 × 10^9/L, a platelet count of at least 100,000/µL, and a hemoglobin of at least 10 g/dL before the first dose. He fails all three thresholds: ANC 1.3, platelets 86,000, and hemoglobin 9.7. In addition, his MRI shows diffuse marrow replacement, which increases the risk of prolonged myelosuppression and makes him a less favorable candidate even if counts are corrected. The prior transfusions also suggest limited marrow reserve. Starting next week without correcting these values would be outside the label and would expose him to a meaningful risk of cytopenias without a clear expectation of benefit.
2. What would you do to optimize his candidacy, and what alternatives would you discuss?
Read the worked answer
First, correct the hemoglobin with transfusion and recheck the complete blood count; if platelets and ANC recover above the thresholds, he may become eligible. If the counts remain low, Ra-223 should not be forced. Discuss alternatives that are less marrow-suppressive or that address his pain, such as palliative radiation to a dominant painful site, optimization of analgesics, or a clinical trial. Denosumab can continue, but it does not correct marrow failure. Repeat marrow assessment may help define the degree of replacement. The conversation should include goals of care, because diffuse marrow involvement and prior docetaxel progression make the expected benefit uncertain. If he does start Ra-223 later, he will need counts before every dose.
3. How do you counsel him about the expected survival benefit and toxicity of Ra-223?
Read the worked answer
In the pivotal trial, Ra-223 improved median overall survival by about 3.6 months compared with placebo (approximately 14.9 versus 11.3 months) and delayed symptomatic skeletal events. It is not a cure, and the benefit in an individual patient with diffuse marrow replacement may be smaller. The main toxicity is myelosuppression, particularly anemia and thrombocytopenia, along with diarrhea, nausea, and fatigue. He should understand that his low counts and marrow replacement increase the risk of treatment interruption or transfusion dependence. He also needs to know that Ra-223 is given every 4 weeks for six doses, that he will be monitored with blood counts before each dose, and that he should report new pain, bleeding, or fever promptly.